Ofloxacin (OFLX), having superior antileprosy activity among the various quinolones, was studied for its combined therapeutic efficacy with rifampin (RMP) against Mycobacterium leprae infection induced in nude mice. When OFLX (3 mg/mouse) was given to infected mice in combination with RMP (0.01 mg/mouse) by gavage once daily six times per week, from day 31 to day 80 postinfection, a significant combined effect was observed. This study demonstrates the possibility of using OFLX in multidrug regimens for the clinical control of bacilliferous leprosy patients.
BT - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association C1 -http://www.ncbi.nlm.nih.gov/pubmed/8396614?dopt=Abstract
DA - 1993 Jun IS - 2 J2 - Int. J. Lepr. Other Mycobact. Dis. LA - eng N2 -Ofloxacin (OFLX), having superior antileprosy activity among the various quinolones, was studied for its combined therapeutic efficacy with rifampin (RMP) against Mycobacterium leprae infection induced in nude mice. When OFLX (3 mg/mouse) was given to infected mice in combination with RMP (0.01 mg/mouse) by gavage once daily six times per week, from day 31 to day 80 postinfection, a significant combined effect was observed. This study demonstrates the possibility of using OFLX in multidrug regimens for the clinical control of bacilliferous leprosy patients.
PY - 1993 SP - 250 EP - 4 T2 - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association TI - Therapeutic efficacy of some new quinolones and a combination of ofloxacin with rifampin against Mycobacterium leprae infection induced in athymic nude mice. UR - http://ila.ilsl.br/pdfs/v61n2a10.pdf VL - 61 SN - 0148-916X ER -